NCT05763082View on ClinicalTrials.gov

Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

August 8, 2023

Study Completion Date

August 8, 2023

Conditions
Plaque Psoriasis
Interventions
DRUG

roflumilast cream 0.3%

test product

DRUG

Zoryve

Reference Listed Drug product

DRUG

Placebo

placebo

Trial Locations (1)

40241

DS Research, Louisville

Sponsors

Lead Sponsor

Padagis LLC
All Listed Sponsors
lead

Padagis LLC

INDUSTRY

NCT05763082 - Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis | Biotech Hunter | Biotech Hunter